Treatment of Acute Cannabinoid Overdose
Summary
USPTO published patent application US20260091020A1 for methods of treating acute cannabinoid intoxication and metrics for evaluating cannabis intoxication. Inventors are Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, and Kenneth C. CUNDY, with application filing date of September 25, 2023.
What changed
The USPTO published patent application US20260091020A1 disclosing methods for treating acute cannabinoid overdose and systems for evaluating cannabis intoxication. The application (A1 publication kind) covers therapeutic approaches and evaluation metrics for cannabis intoxication and its amelioration. CPC classifications include A61K 31/397, A61K 31/658, and A61P 25/30.
Patent applications are informational publications and create no compliance obligations. Pharmaceutical companies, cannabis product manufacturers, and healthcare providers may monitor this application to understand potential patent landscape in overdose treatment. No immediate action is required, though entities in these sectors may wish to track patent prosecution for freedom-to-operate considerations.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF ACUTE CANNABINOID OVERDOSE
Application US20260091020A1 Kind: A1 Apr 02, 2026
Inventors
Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, Kenneth C. CUNDY
Abstract
Provided herein are methods of treating cannabinoid intoxication. Further provided herein are metrics for evaluation Cannabis intoxication and the amelioration thereof.
CPC Classifications
A61K 31/397 A61K 31/658 A61P 25/30
Filing Date
2023-09-25
Application No.
19113693
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.